$0.49 Earnings Per Share Expected for Heska Co. (NASDAQ:HSKA) This Quarter

Equities research analysts forecast that Heska Co. (NASDAQ:HSKAGet Rating) will announce earnings per share (EPS) of $0.49 for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Heska’s earnings, with the lowest EPS estimate coming in at $0.39 and the highest estimate coming in at $0.54. Heska posted earnings of $0.50 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 2%. The firm is expected to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Heska will report full-year earnings of $1.86 per share for the current year, with EPS estimates ranging from $1.37 to $2.28. For the next financial year, analysts anticipate that the company will post earnings of $2.71 per share, with EPS estimates ranging from $2.52 to $3.04. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Heska.

Heska (NASDAQ:HSKAGet Rating) last issued its quarterly earnings data on Monday, May 9th. The medical research company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.16. The firm had revenue of $64.80 million for the quarter, compared to analysts’ expectations of $66.32 million. The business’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.20 EPS.

A number of equities analysts recently issued reports on the company. Zacks Investment Research lowered Heska from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 8th. StockNews.com assumed coverage on Heska in a report on Thursday, March 31st. They set a “hold” rating on the stock. TheStreet lowered Heska from a “c-” rating to a “d+” rating in a report on Friday, February 11th. Piper Sandler lowered their price target on Heska from $210.00 to $190.00 and set an “overweight” rating on the stock in a report on Thursday, March 17th. Finally, JPMorgan Chase & Co. lowered their price target on Heska from $300.00 to $250.00 and set an “overweight” rating on the stock in a report on Wednesday, February 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $220.67.

Large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. lifted its position in Heska by 2.9% in the third quarter. Goldman Sachs Group Inc. now owns 75,263 shares of the medical research company’s stock valued at $19,458,000 after purchasing an additional 2,115 shares during the period. BlackRock Inc. lifted its position in shares of Heska by 3.0% during the 3rd quarter. BlackRock Inc. now owns 1,818,027 shares of the medical research company’s stock valued at $470,032,000 after acquiring an additional 53,285 shares during the period. Voloridge Investment Management LLC lifted its position in shares of Heska by 30.8% during the 3rd quarter. Voloridge Investment Management LLC now owns 13,542 shares of the medical research company’s stock valued at $3,501,000 after acquiring an additional 3,187 shares during the period. Allianz Asset Management GmbH lifted its position in shares of Heska by 13.3% during the 3rd quarter. Allianz Asset Management GmbH now owns 191,664 shares of the medical research company’s stock valued at $49,552,000 after acquiring an additional 22,479 shares during the period. Finally, Sageworth Trust Co of South Dakota acquired a new stake in shares of Heska during the 4th quarter valued at approximately $81,000. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Shares of HSKA stock opened at $84.89 on Friday. The stock’s 50-day moving average is $132.82 and its two-hundred day moving average is $152.07. The firm has a market cap of $915.62 million, a price-to-earnings ratio of -771.73 and a beta of 1.64. Heska has a 1 year low of $82.92 and a 1 year high of $275.94. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.15 and a current ratio of 7.27.

Heska Company Profile (Get Rating)

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers.

Featured Articles

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.